2010
DOI: 10.3109/09553002.2010.518207
|View full text |Cite
|
Sign up to set email alerts
|

Lethal and mutagenic interactions between γ-rays, cisplatin and etoposide at the cellular and molecular levels

Abstract: Synergistic lethal and mutagenic interactions indicate crosstalk between non-homologous end joining, homologous recombination and postreplicative repair pathways. Pt + E additivity indicate independence of involved repair pathways. Furthermore, the quantification of interactive events may be an additional suitable tool in tumour therapy planning.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2012
2012
2018
2018

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 35 publications
0
3
0
Order By: Relevance
“…etoposide, pactitaxel, and Vinca alkaloids, which have not only been recognized as potential radiosensitizers, but already under clinical application in association with cancer radiotherapy (Burris and Hurtig, 2010). Nevertheless, these drugs and their analogs are also under continuous appraisal for further development in this regard (Hiro et al, 2010; Orditura et al, 2010; Lillo et al, 2011; Schwarzenberger et al, 2011). …”
Section: Potential Plant Products For Application In Cancer Radiotherapymentioning
confidence: 99%
“…etoposide, pactitaxel, and Vinca alkaloids, which have not only been recognized as potential radiosensitizers, but already under clinical application in association with cancer radiotherapy (Burris and Hurtig, 2010). Nevertheless, these drugs and their analogs are also under continuous appraisal for further development in this regard (Hiro et al, 2010; Orditura et al, 2010; Lillo et al, 2011; Schwarzenberger et al, 2011). …”
Section: Potential Plant Products For Application In Cancer Radiotherapymentioning
confidence: 99%
“…Based on survival curves ( Figure 1 ) an absorbed dose of 200 Gy was selected for combination treatments. Aliquots of cells were plated in solid nutrient medium YPDA: YPD + 2% agar (DIFCO Laboratories, USA) and incubated at 30°C for 72 h. Survival was calculated as surviving fraction: S(x,y) = Ns/No, where Ns is the number of surviving cells capable of generating visible clones/mL; No is the total number of treated cells/mL; x the absorbed dose of radiation; and y the doses of the putative protectors ( 16 , 17 ).…”
Section: Methodsmentioning
confidence: 99%
“…To determine mutation frequency, cell samples of SC7K lys2-3 were plated after treatment on omission media (OM: 2% dextrose, 0.67% nitrogenous base yeast (Sigma-Aldrich, USA), 2% agar) ( 17 , 18 ) and incubated at 30°C for 21 days. Thereafter, the number of revertants lys → LYS were scored ( 12 , 13 ).…”
Section: Methodsmentioning
confidence: 99%